Barclays
CGEM icon

Barclays’s Cullinan Oncology CGEM Stock Holding History

Barclays’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Buy
143,945
+3,650
+3% +$54.2K ﹤0.01% 2208
2026
Q1 		$1.99M Sell
140,295
-129,360
-48% -$1.66M ﹤0.01% 2356
2025
Q4 		$2.79M Buy
269,655
+18,545
+7% +$167K ﹤0.01% 2682
2025
Q3 		$1.49M Sell
251,110
-17,357
-6% -$127K ﹤0.01% 3107
2025
Q2 		$2.02M Buy
268,467
+27,124
+11% +$218K ﹤0.01% 2837
2025
Q1 		$1.83M Sell
241,343
-3,888
-2% -$37.3K ﹤0.01% 2699
2024
Q4 		$2.99M Sell
245,231
-3,383
-1% -$48.6K ﹤0.01% 2591
2024
Q3 		$4.16M Buy
248,614
+51,300
+26% +$910K ﹤0.01% 2249
2024
Q2 		$3.44M Buy
197,314
+157,122
+391% +$3.35M ﹤0.01% 1766
2024
Q1 		$685K Sell
40,192
-45,032
-53% -$696K ﹤0.01% 3388
2023
Q4 		$868K Buy
85,224
+31,831
+60% +$282K ﹤0.01% 3542
2023
Q3 		$483K Buy
53,393
+31,650
+146% +$330K ﹤0.01% 2829
2023
Q2 		$234K Sell
21,743
-6,570
-23% -$69.8K ﹤0.01% 3170
2023
Q1 		$290K Buy
28,313
+6,817
+32% +$75.2K ﹤0.01% 3595
2022
Q4 		$227K Buy
21,496
+12,502
+139% +$152K ﹤0.01% 3771
2022
Q3 		$116K Buy
8,994
+1,731
+24% +$23.3K ﹤0.01% 3479
2022
Q2 		$93K Sell
7,263
-65
-0.9% -$737 ﹤0.01% 3793
2022
Q1 		$77K Buy
+7,328
New +$99K ﹤0.01% 3909

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Barclays's CGEM Position: Q2 2026 in Review

Barclays increased its Cullinan Oncology (CGEM) stake by 2.6% in Q2 2026, buying an estimated $54.2K and bringing the position to 143,945 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

Barclays first reported a position in CGEM in Q1 2022 and has held it in 18 quarters since. The position peaked at $4.16M in Q3 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Barclays held 143,945 shares of Cullinan Oncology worth $2.62M as of Q2 2026.
  • Barclays bought 3,650 Cullinan Oncology shares in Q2 2026, an estimated $54.2K.
  • Cullinan Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2208 holding.
  • Barclays first reported a position in Cullinan Oncology in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Cullinan Oncology position peaked at $4.16M in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.